Last reviewed · How we verify

Ajovy — Competitive Intelligence Brief

Ajovy (FREMANEZUMAB) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed Calcitonin gene-related peptide 1 Neuroscience Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Ajovy (FREMANEZUMAB) — Teva. Ajovy works by blocking the action of calcitonin gene-related peptide 1 (CGRP1), a molecule involved in pain transmission.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ajovy TARGET FREMANEZUMAB Teva marketed Calcitonin gene-related peptide 1 2018-01-01
Vyepti EPTINEZUMAB Lundbeck Seattle BioPharmaceuticals, Inc. marketed Calcitonin Gene-related Peptide Antagonist [EPC] Calcitonin gene-related peptide 1 2020-01-01
Emgality GALCANEZUMAB Eli Lilly marketed Calcitonin gene-related peptide 1 2018-01-01
VYEPTI EPTINEZUMAB-JJMR Lundbeck Seattle BioPharmaceuticals, Inc. marketed Calcitonin Gene-related Peptide Antagonist [EPC] Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ajovy — Competitive Intelligence Brief. https://druglandscape.com/ci/fremanezumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: